Can open-source R&D reinvigorate drug research?
The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry?
Munos
Bernard
B
Bernard Munos is at Eli Lilly & Co., Lilly Corporate Center, 1085, Indianapolis, Indiana 46285, USA. bhmunos@stanfordalumni.org
D002986:Clinical Trials as Topic / Q000379:methods; D016208:Databases, Factual; D017277:Drug Approval / Q000379:methods; D015195:Drug Design; D006801:Humans; D009936:Organizational Innovation; D012106:Research / Q000458:organization & administration / Q000639:trends; D012107:Research Design; D012984:Software; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends